BusinessHorizon Pharma Gift Establishes First Clinical Team Endowment at Children’s National Rare Disease InstituteBy Nasdaq OMXFeb 26, 2018, 1:02 PM UTC
BusinessHorizon Pharma plc Presents Results from an Open-Label Study on the Use of PROCYSBI® (cysteamine bitartrate) Delayed-Release Capsules in Treatment-Naïve Children Younger than 6 Years of AgeBy Nasdaq OMXNov 4, 2017, 3:00 PM UTC
BusinessHorizon Pharma plc Announces Poster Presentation on KRYSTEXXA® (pegloticase injection) at the American Society of Nephrology Kidney Week 2017By Nasdaq OMXNov 3, 2017, 3:00 PM UTC
BusinessHorizon Pharma plc to Present KRYSTEXXA® (pegloticase injection) Data for the Management of Uncontrolled Gout at the 2017 ACR/ARHP Annual MeetingBy Nasdaq OMXOct 23, 2017, 12:01 PM UTC
BusinessEQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Horizon Pharma plc – HZNPBy Nasdaq OMXApr 12, 2016, 5:44 PM UTC
BusinessSHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Horizon Pharma plcBy Nasdaq OMXMar 11, 2016, 9:13 PM UTC
